AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

BioMidwest

Investors: Making the Case for Pfizer or AbbVie

For investors looking for a big pharma stock, AbbVie and Pfizer are both top choices.

May 23, 2018

3 min read

Mark Terry

Deals

A Behind-the-Scenes Look at Takeda Pharma’s Takeover of Shire

The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal.

May 14, 2018

3 min read

Mark Terry

Drug Development

ICER Report Suggest AbbVie’s Elagolix Could Strain Healthcare Budgets

Not only does the company have to deal with the U.S. Food and Drug Administration’s three month PDUFA delay for elagolix, but now the watchdog organization, The Institute for Clinical and Economic Review (ICER), has released some disconcerting news over pricing.

May 9, 2018

3 min read

Alex Keown

Network Technology Cooperation and Transaction

Business

Lodo Therapeutics and Genentech Ink Strategic Collaboration Potentially Worth $1 Billion or More

Lodo Therapeutics, based in New York, formed a strategic drug discovery collaboration with Genentech, a Roche company, in a deal potentially worth more than $1 billion.

May 9, 2018

3 min read

Mark Terry

FDA

The Top 5 Upcoming Biosimilar Approvals in the U.S.

According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.

May 3, 2018

3 min read

Mark Terry

Business

FDA Issues Complete Response Letter to Novartis’ Copycat of Roche’s Rituxan

The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.

May 3, 2018

2 min read

Mark Terry

BioMidwest

Review of Top Biotech Stocks for May 2018

To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth a look this month for different reasons.

May 2, 2018

4 min read

Mark Terry

Business

Strong Sales of Humira, Imbruvica and HCV Drug Mavyret Drive AbbVie’s Strong First Quarter

Humira, the world’s best-selling drug, keeps on churning out positive sales results for AbbVie, despite looming challenges.

April 26, 2018

3 min read

Alex Keown

Black clock with Review time, three-dimensional rendering, 3D illustration

Policy

Eli Lilly and Incyte Shares Drop as FDA Raises Concerns about Arthritis Drug

Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.

April 19, 2018

2 min read

Mark Terry

JOBS